Report: The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends) TOC

Overview
Structural Organization of the Neurological System
- Central Nervous System
- The Brain
Aging and Alzheimer' s Disease
Stages of Alzheimer' s Disease
Risk Factors
Life Expectancy and the Growing Incidence of Alzheimer' s Disease
World Demographics
Prevalence, Incidence and Mortality
Insurance for the Elderly in the United States
Generic Competition
- Teva/Mutual Pharmaceutical/United Research Laboratories and Eisai
- Dr. Reddy' s and Novartis
- Ranbaxy and Ortho-McNeil Neurologics

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER TWO: INTRODUCTION

Table 2-1: Alzheimer' s Disease Stages 1-7 and Descriptions
Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2006
Figure 2-1: Average Life Expectancy in Years by Country 1980, 2004 and 2006
Table 2-3: World Population by Selected Geographical Region, 2007 - 2050
Figure 2-2: World Population by Selected Geographical Region, 2007-2050
Table 2-4: Estimated World Population by Age and Geographical Region, 2007
Figure 2-3: Estimated World Population by Age and Geographical Region, 2007
Table 2-5: Percent Population Over 65 by Year and Region
Figure 2-4: Estimated World Population by Age, 2007 and 2050
Table 2-6: Estimated Prevalence, Incidence and Mortality for Alzheimer' s Disease* by Region/Country, 2007
Figure 2-5: Estimated World Prevalence and Incidence of Alzheimer' s Diseases by Region, 2007
Figure 2-6: World Prevalence of Alzheimer' s Disease Compared to Rest of Population Over Age 65, 2007
Table 2-7: Health Insurance Trends in the United States, Estimated 2007 (millions)

CHAPTER THREE: ALZHEIMER' S DISEASE PRODUCT ANALYSIS

CHAPTER FOUR: RESEARCH AND DEVELOPMENT

Figure 4-1: Alzheimer' s Disease Treatments in Development, 2005, 2006, and 2007
Table 4-1: Alzheimer' s Disease Therapies in Development

CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS

Table 5-1: Alzheimer' s Disease Market Analysis, 2005-2007
Table 5-2: Forecasted Alzheimer' s Disease Market Analysis: 2008-2012
Figure 5-1: Alzheimer' s Disease Market Analysis: 2005-2012
Table 5-3: Alzheimer' s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
Figure 5-2: Alzheimer' s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
Figure 5-3: Alzheimer' s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005 Figure 5-4: Alzheimer' s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2007
Table 5-4: Alzheimer' s Disease Market Analysis by Region/Country, 2007
Figure 5-5: Alzheimer' s Disease Market Analysis by Region/Country, 2007
Table 5-5: Alzheimer' s Disease Market Estimated Revenues and Market Share of Leading Suppliers 2007
Figure 5-6: Alzheimer' s Disease Market Estimated Market Share by Leading Suppliers 2007
Table 5-6: Alzheimer' s Disease Market Estimated Sales of Top Products 2007
Figure 5-7 : Alzheimer' s Disease Market Estimated Market Share of Top Products, 2007

CHAPTER SIX: LEADING MANUFACTURERS

Figure 6-1: Eisai' s Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-2: Forest' s Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-3: Lundbeck' s Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-4: Johnson & Johnson' s Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-5: Merz Pharma' s Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-6: Novartis' Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-7: Pfizer' s Net Revenues and R&D Expenses for 2006 and 2007

The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)